Cargando…

Challenges with PCSK9 Inhibitors Use in Asia Given Real-World Data Implications

Detalles Bibliográficos
Autor principal:	Uno-Eder, Kiyoko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499451/ https://www.ncbi.nlm.nih.gov/pubmed/36948635 http://dx.doi.org/10.5551/jat.ED230

Ejemplares similares

Real-world use of PCSK9 inhibitors: A single-center experience
por: Sarsam, Sinan, et al.
Publicado: (2018)

PCSK9 Inhibitor Use in the Real World: Data From the National Patient‐Centered Research Network
por: Chamberlain, Alanna M., et al.
Publicado: (2019)

Adverse Events Associated With PCSK9 Inhibitors: A Real‐World Experience
por: Gürgöze, Muhammed T., et al.
Publicado: (2018)

Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study
por: Blanco-Ruiz, Marina, et al.
Publicado: (2021)

Just Price for PCSK9 Inhibitors: No less, No More
por: Nasir, Khurram
Publicado: (2018)

PCSK9 Inhibitors: What Lies Beyond Monoclonal Antibodies?
por: EBioMedicine
Publicado: (2015)

Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
por: Feng, Zhen, et al.
Publicado: (2022)

Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus
por: Fischer, Laurenz T., et al.
Publicado: (2021)

The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research
por: Elguindy, Ahmed, et al.
Publicado: (2013)

PCSK9 inhibition in high-risk patients
por: Zijlstra, Laurien E., et al.
Publicado: (2019)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan
por: Lin, Po-Lin, et al.
Publicado: (2023)

PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology
por: Altschmiedová, Tereza, et al.
Publicado: (2022)

PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients
por: Ceballos-Macías, José Juan, et al.
Publicado: (2020)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

PCSK9 Inhibition: Does Lipoprotein Size Matter?
por: Si‐Tayeb, Karim, et al.
Publicado: (2015)

PCSK9 and carbohydrate metabolism: A double-edged sword
por: Filippatos, Theodosios D, et al.
Publicado: (2017)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

PCSK9 inhibitors in the prevention of cardiovascular disease
por: Latimer, James, et al.
Publicado: (2016)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
por: Péč, Martin Jozef, et al.
Publicado: (2023)

Statement for Appropriate Clinical Use of PCSK9 Inhibitors
por: Nohara, Atsushi, et al.
Publicado: (2018)

Finding inhibitors for PCSK9 using computational methods
por: Zainab, Rida, et al.
Publicado: (2021)

Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study)
por: LIU, Yu-Qi, et al.
Publicado: (2021)

Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study
por: Seijas-Amigo, Jose, et al.
Publicado: (2023)

Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis
por: Matta, Anthony, et al.
Publicado: (2021)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
por: Zulkapli, Rahayu, et al.
Publicado: (2023)

SUN-573 Use of PCSK9 Inhibitors Post-Transplant
por: Matthews, Juliana, et al.
Publicado: (2020)

Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
por: Warden, Bruce A., et al.
Publicado: (2020)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
por: Kosmas, Constantine E, et al.
Publicado: (2020)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
por: Pęczek, Piotr, et al.
Publicado: (2021)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
por: Tomlinson, Brian, et al.
Publicado: (2021)

Anti‐PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care
por: Descamps, Olivier S., et al.
Publicado: (2017)

The multimorbidity epidemic: challenges for real-world research
por: Adan, Muna, et al.
Publicado: (2020)

Digital Health and Big Data Analytics: Implications of Real-World Evidence for Clinicians and Policymakers
por: Magalhães, Teresa, et al.
Publicado: (2022)

Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
por: Xia, Xiao-dan, et al.
Publicado: (2021)

Sex difference in circulating PCSK9 and its clinical implications
por: Jia, Fang, et al.
Publicado: (2022)

Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice
por: Fairman, Kathleen A, et al.
Publicado: (2017)

Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) on Lipid Metabolism and Insulin Resistance in Human
por: Muraki, Isao
Publicado: (2021)

PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks
por: Hollstein, Tim, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fj7sqemaev7b92r9nsv3ps3rha